Joaquim Mullol
Grupo de investigación
- Inmunoalergia respiratoria clínica y experimental (IRCE) Group leader (R4)
Publicaciones destacadas
-
EUFOREA Consensus on Biologics for CRSwNP with or without asthma
Autores: Fokkens WJ; Lund V; Bachert C; Mullol J; Bjermer L; Bousquet J; Canonica GW; Deneyer L; Desrosiers M; Diamant Z; Han J; Heffler E; Hopkins C; Jankowski R; Joos G; Knill A; Lee J; Lee SE; Mariën G; Pugin B; Senior B; Seys SF; Hellings PW .Referencia: Allergy 2019. -
Olfactory Training Prevents Olfactory Dysfunction Induced by Bulbar Excitotoxic Lesions: Role of Neurogenesis and Dopaminergic Interneurons
Autores: Marin C, Laxe S, Langdon C, Alobid I, Berenguer J, Fuentes M, Bernabeu M, Mullol J .Referencia: Molecular Neurobiology 2019. -
Recovery of Olfactory Function After Excitotoxic Lesion of the Olfactory Bulbs Is Associated with Increases in Bulbar SIRT1 and SIRT4 Expressions
Autores: Marin C; Langdon C; Alobid I; Fuentes M; Bonastre M; Mullol J.Referencia: Molecular Neurobiology 2019. -
Olfactory training in posttraumatic smell impairment: mild improvement in threshold performances - results from a randomized controlled trial.
Autores: Langdon C, Lehrer E, Berenguer J, Laxe S, Alobid I, Quintó L, Mariño-Sánchez F, Bernabeu M, Marin C, Mullol J .Referencia: Journal Of Neurotrauma 2018. -
Smell loss is associated with severe and uncontrolled disease in children and adolescents with persistent allergic rhinitis.
Autores: Mariño-Sanchez F, Valls-Mateus M, Haag O, Alobid I, Bousquet J, Mullol J .Referencia: Journal Of Allergy And Clinical Immunology 2018. -
Nasal obstructive disorders impair health-related quality of life in adolescents with persistent allergic rhinitis: a real-life study.
Autores: Valls-Mateus M, Marino-Sanchez F, Ruiz-Echevarría K, Cardenas-Escalante P, Jiménez-Feijoo R, Blasco-Lozano J, Giner-Muñoz MT, Haag O, Alobid I, Plaza Martin AM, Mullol J .Referencia: Pediatric Allergy And Immunology 2017. -
Position paper on olfactory dysfunction
Autores: Hummel T; Whitcroft KL; Andrews P; Altundag A; Cinghi C; Costanzo RM; Damm M; Frasnelli J; Gudziol H; Gupta N; Haehner A; Holbrook E; Hong SC; Hornung D; Hüttenbrink KB; Kamel R; Kobayashi M; Konstantinidis I; Landis BN; Leopold DA; Macchi A; Miwa T; Moesges R; Mullol J; Mueller CA; Ottaviano G; Passali GC; Philpott C; Pinto JM; Ramakrishnan VJ; Rombaux P; Roth Y; Schlosser RA; Shu B; Soler G; Stjärne P; Stuck BA; Vodicka J; Welge-Luessen A.Referencia: Rhinology. Supplement 2017. -
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial
Autores: Bachert C; Mannent L; Naclerio RM; Mullol J; Ferguson BJ; Gevaert P; Hellings P; Jiao L; Wang L; Evans RR; Pirozzi G; Graham NM; Swanson B; Hamilton JD; Radin A; Gandhi NA; Stahl N; Yancopoulos GD; Sutherland ER .Referencia: Jama-Journal Of The American Medical Association 2016. -
Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a population-based survey (OLFACAT study)
Autores: Mullol, Joaquim; Alobid, Isam; Marino-Sanchez, Franklin; Quinto, Llorenc; de Haro, Josep; Bernal-Sprekelsen, Manuel; Valero, Antonio; Picado, Cesar; Marin, Concepcio.Referencia: Bmj Open 2012. -
EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists
Autores: Fokkens, Wytske J; Lund, Valerie J; Mullol, Joachim; Bachert, Claus; Alobid, Isam; Baroody, Fuad; Cohen, Noam; Cervin, Anders; Douglas, Richard; Gevaert, Philippe; Georgalas, Christos; Goossens, Herman; Harvey, Richard; Hellings, Peter; Hopkins, Claire; Jones, Nick; Joos, Guy; Kalogjera, Livije; Kern, Bob; Kowalski, Marek; Price, David; Riechelmann, Herbert; Schlosser, Rodney; Senior, Brent; Thomas, Mike; Toskala, Elina; Voegels, Richard; Wang, de Yun; Wormald, Peter John.Referencia: Rhinology 2012.
Proyectos destacados
-
Papel de los microRNA en la modulación in vitro de la diferenciación mucociliar e inflamación del epitelio nasosinusal en la poliposis nasal
Investigador/a principal: Joaquim Mullol I MiretFinanciador: Fondo de Investigación Sanitaria (FIS) Instituto de Salud Carlos III, Ministerio de Sanidad y ConsumoCódigo: PI18-00469Duración: 01/01/2019 - 31/12/2021 -
Expression of Rupatadine on PAF-induced inflammation in blood eosinophils and epithelial cells from nasal polyps and healthy nasal mucosa (RINOPAF-2 Study).
Investigador/a principal: Joaquim Mullol I MiretFinanciador: URIACH S.ACódigo: RINOPAF-02-2018Duración: 01/01/2019 - 31/12/2021 -
Función reguladora de los microRNA sobre los genes diana involucrados en la diferenciación epitelial de la mucosa nasosinusal en la poliposis nasal.
Investigador/a principal: Joaquim Mullol I MiretFinanciador: Fondo de Investigación Sanitaria (FIS) Instituto de Salud Carlos III, Ministerio de Sanidad y ConsumoCódigo: PI15-00046Duración: 01/01/2016 - 31/12/2019 -
Estudio de los mecanismos por los cuales el Omalizumab es capaz de mejorar el asma persistente asociada a la Enfermedad Respiratoria Exacerbada por AINES (EREA)
Investigador/a principal: Irina BoboleaCódigo: SEPAR'18Duración: 01/01/2019 - 31/12/2021 -
Study of the antiinflammatory mechanisms of action of MP29-02, compared to fluticasone propionate and azelastine alone, in healthy and inflamed human ansal mucosa: regulation on anti- and pro-inflammatory genes and GR.
Investigador/a principal: Joaquim Mullol I MiretCódigo: DYMECOS IIDuración: 01/01/2016 - 31/12/2019